This program of work uses quantitative and qualitative research methods to examine how different labels for low risk cancer (thyroid, breast, prostate) impact treatment decision making and patient outcomes. It aims to engage patients and clinicians, including pathologists, to consider the recalibration of the cancer diagnostic threshold and/or revisions to terminology used for low risk lesions, and to test proposed solutions which can be implemented into policy and practice internationally.

Led by: Dr Brooke Nickel